Cargando…

Engineering precision nanoparticles for drug delivery

In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Michael J., Billingsley, Margaret M., Haley, Rebecca M., Wechsler, Marissa E., Peppas, Nicholas A., Langer, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717100/
https://www.ncbi.nlm.nih.gov/pubmed/33277608
http://dx.doi.org/10.1038/s41573-020-0090-8
_version_ 1783619288997822464
author Mitchell, Michael J.
Billingsley, Margaret M.
Haley, Rebecca M.
Wechsler, Marissa E.
Peppas, Nicholas A.
Langer, Robert
author_facet Mitchell, Michael J.
Billingsley, Margaret M.
Haley, Rebecca M.
Wechsler, Marissa E.
Peppas, Nicholas A.
Langer, Robert
author_sort Mitchell, Michael J.
collection PubMed
description In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.
format Online
Article
Text
id pubmed-7717100
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77171002020-12-07 Engineering precision nanoparticles for drug delivery Mitchell, Michael J. Billingsley, Margaret M. Haley, Rebecca M. Wechsler, Marissa E. Peppas, Nicholas A. Langer, Robert Nat Rev Drug Discov Review Article In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall. Nature Publishing Group UK 2020-12-04 2021 /pmc/articles/PMC7717100/ /pubmed/33277608 http://dx.doi.org/10.1038/s41573-020-0090-8 Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Mitchell, Michael J.
Billingsley, Margaret M.
Haley, Rebecca M.
Wechsler, Marissa E.
Peppas, Nicholas A.
Langer, Robert
Engineering precision nanoparticles for drug delivery
title Engineering precision nanoparticles for drug delivery
title_full Engineering precision nanoparticles for drug delivery
title_fullStr Engineering precision nanoparticles for drug delivery
title_full_unstemmed Engineering precision nanoparticles for drug delivery
title_short Engineering precision nanoparticles for drug delivery
title_sort engineering precision nanoparticles for drug delivery
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717100/
https://www.ncbi.nlm.nih.gov/pubmed/33277608
http://dx.doi.org/10.1038/s41573-020-0090-8
work_keys_str_mv AT mitchellmichaelj engineeringprecisionnanoparticlesfordrugdelivery
AT billingsleymargaretm engineeringprecisionnanoparticlesfordrugdelivery
AT haleyrebeccam engineeringprecisionnanoparticlesfordrugdelivery
AT wechslermarissae engineeringprecisionnanoparticlesfordrugdelivery
AT peppasnicholasa engineeringprecisionnanoparticlesfordrugdelivery
AT langerrobert engineeringprecisionnanoparticlesfordrugdelivery